Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma

The first line therapy for patients with diffuse large B cell (DLBCL) is R-CHOP. About half of DLBCL patients are either refractory to, or will relapse, after the treatment. Therefore, identifying novel drug t...

Source: Journal of Experimental and Clinical Cancer Research - November 6, 2019 Category: Cancer & Oncology Authors: Liling Jiang, Yuening Sun, Jinxiang Wang, Qingyan He, Xinmei Chen, Xiaoying Lan, Jinghong Chen, Q. Ping Dou, Xianping Shi and Jinbao Liu Tags: Research Source Type: research